NO20076059L - 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer - Google Patents

2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer

Info

Publication number
NO20076059L
NO20076059L NO20076059A NO20076059A NO20076059L NO 20076059 L NO20076059 L NO 20076059L NO 20076059 A NO20076059 A NO 20076059A NO 20076059 A NO20076059 A NO 20076059A NO 20076059 L NO20076059 L NO 20076059L
Authority
NO
Norway
Prior art keywords
diamino
aurora inhibitors
pyrimidines used
pyrimidines
aurora
Prior art date
Application number
NO20076059A
Other languages
English (en)
Norwegian (no)
Inventor
Ulrike Tontsch-Grunt
Flavio Solca
Matthias Treu
Stephan Karl Zahn
Guido Boehmelt
Andreas Mantoulidis
Ulrich Reiser
Ulrich Guertler
Andreas Schoop
Ralph Brueckner
Charlotte Reither
Lars Herfurth
Oliver Kraemer
Heinz Stadtmueller
Harald Engelhardt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20076059L publication Critical patent/NO20076059L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20076059A 2005-07-01 2007-11-26 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer NO20076059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106007 2005-07-01
PCT/EP2006/063736 WO2007003596A1 (de) 2005-07-01 2006-06-30 2,4-diamino-pyrimidine als aurora inhibitoren

Publications (1)

Publication Number Publication Date
NO20076059L true NO20076059L (no) 2008-01-30

Family

ID=35431858

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076059A NO20076059L (no) 2005-07-01 2007-11-26 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer

Country Status (30)

Country Link
US (3) US20070032514A1 (ja)
EP (1) EP1902037B1 (ja)
JP (1) JP5179357B2 (ja)
KR (1) KR20080031362A (ja)
CN (1) CN101213179A (ja)
AR (1) AR057423A1 (ja)
AT (1) ATE441639T1 (ja)
AU (1) AU2006264958B2 (ja)
BR (1) BRPI0613096A2 (ja)
CA (1) CA2613664A1 (ja)
CY (1) CY1109644T1 (ja)
DE (1) DE502006004750D1 (ja)
DK (1) DK1902037T3 (ja)
EA (1) EA016358B1 (ja)
EC (1) ECSP078060A (ja)
ES (1) ES2330045T3 (ja)
IL (1) IL188452A (ja)
MX (1) MX2007015992A (ja)
MY (1) MY142496A (ja)
NO (1) NO20076059L (ja)
NZ (1) NZ565475A (ja)
PE (1) PE20070121A1 (ja)
PL (1) PL1902037T3 (ja)
PT (1) PT1902037E (ja)
SI (1) SI1902037T1 (ja)
TW (1) TWI369351B (ja)
UA (1) UA92355C2 (ja)
UY (1) UY29636A1 (ja)
WO (1) WO2007003596A1 (ja)
ZA (1) ZA200709763B (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (en) 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8623887B2 (en) * 2006-05-15 2014-01-07 Boehringer Ingelheim International Gmbh Compounds
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US20100144706A1 (en) * 2006-12-22 2010-06-10 Boehringer Ingelheim International Gmbh Compounds
US20100056524A1 (en) * 2008-04-02 2010-03-04 Mciver Edward Giles Compound
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072938A1 (es) 2008-08-20 2010-09-29 Southern Res Inst Derivados de piridina y pirimidina azosustituidos y su uso en el tratamiento de infecciones virales
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TWI409265B (zh) * 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
EP2161259A1 (de) 2008-09-03 2010-03-10 Bayer CropScience AG 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide
CA2735420C (en) * 2008-09-08 2016-06-28 Merck Patent Gmbh Macrocyclic pyrimidines as protein kinase inhibitors
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2440548A1 (en) 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
US20120107304A1 (en) * 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
CA2797947C (en) 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
HUE037844T2 (hu) 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
AU2012221927B2 (en) * 2011-02-25 2016-04-28 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
PT2970205T (pt) 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
MX2016007898A (es) * 2013-12-20 2016-10-07 Signal Pharm Llc Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
GB2538476B (en) 2014-05-08 2019-03-20 Tosoh F Tech Inc 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same
US10710983B2 (en) * 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
MX2020010437A (es) * 2018-04-05 2021-01-29 Sumitomo Pharma Oncology Inc Inhibidores de axl cinasa y uso de los mismos.
CA3103995A1 (en) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367130A1 (en) * 2001-05-29 2005-02-21 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US7169836B2 (en) * 2001-06-27 2007-01-30 Polyplastics Co., Ltd Flame-retardant resin composition
UY27487A1 (es) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7511137B2 (en) * 2003-12-19 2009-03-31 Rigel Pharmaceuticals, Inc. Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
WO2005095357A2 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
CN102127058A (zh) * 2004-05-14 2011-07-20 辉瑞产品有限公司 治疗异常细胞生长的嘧啶衍生物
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US20060142572A1 (en) * 2004-12-14 2006-06-29 Gabriel Martinez-Botella Inhibitors of ERK protein kinase and uses thereof
EA014551B1 (ru) * 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Пиримидиновые производные для лечения аномального клеточного роста

Also Published As

Publication number Publication date
JP2008544972A (ja) 2008-12-11
IL188452A (en) 2012-02-29
PL1902037T3 (pl) 2010-02-26
CA2613664A1 (en) 2007-01-11
KR20080031362A (ko) 2008-04-08
BRPI0613096A2 (pt) 2010-12-21
AR057423A1 (es) 2007-12-05
EP1902037B1 (de) 2009-09-02
MY142496A (en) 2010-11-30
ES2330045T3 (es) 2009-12-03
CY1109644T1 (el) 2014-08-13
UY29636A1 (es) 2007-01-31
MX2007015992A (es) 2008-03-07
IL188452A0 (en) 2008-04-13
AU2006264958A1 (en) 2007-01-11
NZ565475A (en) 2010-01-29
DK1902037T3 (da) 2009-12-21
US20070032514A1 (en) 2007-02-08
AU2006264958B2 (en) 2012-05-03
SI1902037T1 (sl) 2010-01-29
JP5179357B2 (ja) 2013-04-10
UA92355C2 (en) 2010-10-25
PT1902037E (pt) 2009-10-13
ZA200709763B (en) 2008-12-31
DE502006004750D1 (de) 2009-10-15
EA200800172A1 (ru) 2008-08-29
CN101213179A (zh) 2008-07-02
ATE441639T1 (de) 2009-09-15
TWI369351B (en) 2012-08-01
ECSP078060A (es) 2008-01-23
US20110251174A1 (en) 2011-10-13
WO2007003596A1 (de) 2007-01-11
PE20070121A1 (es) 2007-03-05
EA016358B1 (ru) 2012-04-30
TW200726753A (en) 2007-07-16
EP1902037A1 (de) 2008-03-26
US20130281429A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20091626L (no) MGLUR5-modulatorer
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20084005L (no) Aminderivater
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO20090628L (no) Pyridizinon derivativater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20091599L (no) Kjemiske forbindelser
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20082496L (no) Pyrazinderivater
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
NO20081217L (no) Nye benzotiazolonderivater
WO2009003999A3 (en) Chemical compounds
WO2006093547A3 (en) Novel lipoxygenase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application